MarketCapExport financials
Aldeyra Therapeutics (ALDX)
The export includes the complete available history of financial statements and ratios. Numbers are provided in full, without million or billion abbreviations, in their original reporting units.
CSV downloads as a ZIP archive with one file for each report and frequency.
Facebook
X
Telegram
Aldeyra Therapeutics Balance Sheet 2025-2011 | ALDX
Brief overview of Aldeyra Therapeutics's balance sheet strength
This overview follows the five latest available annual observations between 2021 and 2025.
Assets finished at $72.1 million versus $233.1 million initially, losing -69.1%. The balance sheet contracted.
Liability growth of +1.5% exceeded asset growth of -69.1%, increasing reliance on outside funding.
Equity funds 61.4% of assets versus 88.2% initially. This creates a conservative balance sheet structure.
The cash reserve occupies 97.2% of the balance sheet, previously 98.6%. It is one marker of short-term resilience.
Retained earnings remain negative at -$484 million. This may reflect past losses or substantial shareholder distributions, so earnings and buybacks provide important context.
Overall picture
Aldeyra Therapeutics's balance sheet looks stretched: reliance on liabilities and a limited capital cushion increase sensitivity to weaker results.
Annual Balance Sheet Aldeyra Therapeutics
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Net Debt |
- | -39.3 M | - | -129 M | -214 M | -62.8 M | -29.7 M | -47.4 M | -18.7 M | -10.7 M | -13.4 M | -7.27 M | -1.99 M | -791 K | 1.95 M |
Long Term Debt |
- | 15 M | - | 14.9 M | 15.5 M | 11.4 M | 14.5 M | - | 1.22 M | 1.24 M | 1.21 M | 1.18 M | 1.13 M | 266 K | - |
Long Term Debt Current |
281 K | 272 K | 239 K | 249 K | 230 K | 233 K | 226 K | - | 116 K | 77.5 K | 77.5 K | 77.5 K | - | - | - |
Total Non Current Liabilities |
- | 15 M | 6.27 M | 14.9 M | 15.6 M | 11.4 M | 14.5 M | - | 1.22 M | 1.24 M | 1.21 M | 1.18 M | 1.52 M | 26.8 M | - |
Total Current Liabilities |
27.8 M | 18.6 M | 22.3 M | 15.4 M | 11.8 M | 12.4 M | 12.9 M | 8.47 M | 3.35 M | 2.3 M | 2.12 M | 1.33 M | - | - | - |
Total Liabilities |
27.8 M | 33.6 M | 28.5 M | 30.3 M | 27.4 M | 23.8 M | 27.4 M | 8.47 M | 4.57 M | 3.54 M | 3.33 M | 2.5 M | 2.13 M | 27.1 M | 2.59 M |
Deferred Revenue |
6 M | 6 M | - | - | - | - | - | - | - | - | - | - | - | - | - |
Retained Earnings |
-484 M | -450 M | -394 M | -357 M | -295 M | -237 M | -199 M | -139 M | -99.6 M | -77.3 M | -58.6 M | -46.5 M | -41.3 M | -54.4 M | -15.5 M |
Total Assets |
72.1 M | 105 M | 148 M | 181 M | 233 M | 83.4 M | 75.5 M | 95.1 M | 44.2 M | 25.2 M | 28.2 M | 8.79 M | 3.74 M | 1.98 M | 259 K |
Cash and Cash Equivalents |
70 M | 54.5 M | 143 M | 144 M | 230 M | 77.9 M | 44.4 M | 47.4 M | 20 M | 12 M | 14.6 M | 8.53 M | 3.26 M | - | - |
Book Value |
44.3 M | 71 M | 120 M | 151 M | 206 M | 59.5 M | 48.1 M | 86.6 M | 39.6 M | 21.6 M | 24.9 M | 6.28 M | 1.61 M | -25.2 M | -2.33 M |
Total Shareholders Equity |
44.3 M | 71 M | 120 M | 151 M | 206 M | 59.5 M | 48.1 M | 86.6 M | 39.6 M | 21.6 M | 24.9 M | 6.28 M | -40.2 M | - | - |
Annual performance
Select metrics to display
All numbers in USD currency
Quarterly Balance Sheet Aldeyra Therapeutics
| 2026-Q3 | 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Long Term Debt |
280 K | - | - | - | 72.5 K | 143 K | 213 K | 15 M | 70.2 K | 139 K | 206 K | 272 K | 2.66 M | 10.1 M | 15 M | 14.9 M | 3.3 M | - | 63.3 K | 125 K | 185 K | 15.3 M | 10.1 M | 11.4 M | 11.4 M | 11.4 M | 11.4 M | 14.5 M | 58.7 K | 116 K | 157 K | 16 M | 883 K | 995 K | 1.11 M | 1.4 M | 905 K | 1.02 M | 1.13 M | 1.4 M | 883 K | 993 K | 1.1 M | 1.4 M | 1.28 M | 962 K | 1.07 M | 1.4 M | 1.24 M | 816 K | 972 K | 1.13 M | 1.13 M | 1.13 M | 1.13 M | - | - | - | - | - | - | - | - |
Total Non Current Liabilities |
280 K | - | - | - | 72.5 K | 143 K | 15.3 M | 15 M | 15.1 M | 139 K | 6.21 M | 6.27 M | 2.66 M | 10.1 M | 15 M | 14.9 M | 3.3 M | 10.7 M | 15.6 M | 15.6 M | 15.6 M | 15.3 M | 10.1 M | 11.4 M | 12.7 M | 13.9 M | 14.7 M | 14.5 M | 14.4 M | 116 K | 157 K | - | 883 K | 995 K | 1.11 M | 1.22 M | 905 K | 1.02 M | 1.13 M | 1.24 M | 883 K | 993 K | 1.1 M | 1.21 M | 1.28 M | 962 K | 1.07 M | 1.18 M | 1.24 M | 816 K | 3.34 M | - | - | - | - | - | - | - | - | - | - | - | - |
Total Liabilities |
8.16 M | 9.66 M | 24.3 M | 27.8 M | 28.6 M | 29.7 M | 29.6 M | 33.6 M | 32.2 M | 27.7 M | 27.9 M | 28.5 M | 24.3 M | 25.7 M | 31 M | 30.3 M | 27.5 M | 27 M | 32 M | 27.4 M | 27.5 M | 22.7 M | 21.2 M | 23.8 M | 19.2 M | 18.8 M | 19.6 M | 27.4 M | 26.6 M | 6.51 M | 9.65 M | 8.47 M | 8.54 M | 6.31 M | 4.77 M | 4.57 M | 3.32 M | 3.13 M | 3.54 M | 3.54 M | 3.52 M | 3.37 M | 2.91 M | 3.33 M | 2.66 M | 2.35 M | 2.1 M | 2.5 M | 2.09 M | 1.99 M | 4.03 M | 5.65 M | 5.65 M | 5.65 M | 5.65 M | - | - | - | - | - | - | - | - |
Deferred Revenue |
- | - | - | 6 M | - | - | - | 6 M | 6 M | 6 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Retained Earnings |
-497 M | -493 M | -487 M | -484 M | -477 M | -470 M | -460 M | -450 M | -434 M | -419 M | -402 M | -394 M | -390 M | -381 M | -372 M | -357 M | -344 M | -329 M | -311 M | -295 M | -279 M | -263 M | -248 M | -237 M | -226 M | -217 M | -209 M | -199 M | -186 M | -167 M | -154 M | -139 M | -128 M | -117 M | -108 M | -99.6 M | -92.7 M | -87.7 M | -82.4 M | -77.3 M | -72.6 M | -67.9 M | -63.6 M | -58.6 M | -54.2 M | -50.9 M | -48.6 M | -46.5 M | -44.1 M | -42.1 M | -46.5 M | -41.3 M | -41.3 M | -41.3 M | - | - | - | - | - | - | - | - | - |
Total Assets |
43.4 M | 47.5 M | 66.5 M | 72.1 M | 77.8 M | 85 M | 93.2 M | 105 M | 117 M | 126 M | 141 M | 148 M | 147 M | 156 M | 168 M | 181 M | 190 M | 201 M | 223 M | 233 M | 247 M | 256 M | 147 M | 83.4 M | 88.3 M | 71.6 M | 63 M | 75.5 M | 77.4 M | 73.8 M | 88.1 M | 95.1 M | 37.1 M | 43.3 M | 40.8 M | 44.2 M | 49.2 M | 26.5 M | 31.5 M | 25.2 M | 29.2 M | 32.9 M | 23.4 M | 28.2 M | 31.4 M | 33.9 M | 15.9 M | 8.79 M | 10.4 M | 11.8 M | 2.89 M | 3.74 M | 3.74 M | 3.74 M | 3.74 M | - | - | - | - | - | - | - | - |
Cash and Cash Equivalents |
41 M | 45.1 M | 65 M | 70 M | 59.3 M | 41.2 M | 50.4 M | 54.5 M | 68.1 M | 71 M | 102 M | 143 M | 143 M | 152 M | 165 M | 144 M | 129 M | 121 M | 159 M | 230 M | 241 M | 250 M | 138 M | 77.9 M | 86.2 M | 60.7 M | 38.5 M | 44.4 M | 51.6 M | 39.4 M | 44.3 M | 47.4 M | 18 M | 5.43 M | 1.35 M | 20 M | 1.04 M | 1.2 M | 8.71 M | 395 K | 425 K | 1.06 M | 1.13 M | 1.66 M | 30.6 M | 33.6 M | 15.7 M | 8.53 M | 10.1 M | 11.5 M | 2.15 M | 3.26 M | 3.26 M | 3.26 M | 3.26 M | 1.22 M | - | - | - | - | - | - | - |
Book Value |
35.2 M | 37.9 M | 42.2 M | 44.3 M | 49.2 M | 55.3 M | 63.6 M | 71 M | 85.1 M | 98.3 M | 113 M | 120 M | 123 M | 130 M | 137 M | 151 M | 162 M | 174 M | 191 M | 206 M | 220 M | 234 M | 126 M | 59.5 M | 69.2 M | 52.8 M | 43.5 M | 48.1 M | 50.9 M | 67.3 M | 78.5 M | 86.6 M | 28.6 M | 37 M | 36 M | 39.6 M | 45.9 M | 23.3 M | 28 M | 21.6 M | 25.7 M | 29.5 M | 20.5 M | 24.9 M | 28.7 M | 31.5 M | 13.8 M | 6.28 M | 8.26 M | 9.81 M | -1.14 M | -1.9 M | -1.9 M | -1.9 M | -1.9 M | - | - | - | - | - | - | - | - |
Total Shareholders Equity |
35.2 M | 37.9 M | 42.2 M | 44.3 M | 49.2 M | 55.3 M | 63.6 M | 71 M | 85.1 M | 98.3 M | 113 M | 120 M | 123 M | 130 M | 137 M | 151 M | 162 M | 174 M | 191 M | 206 M | 220 M | 234 M | 126 M | 59.5 M | 69.2 M | 52.8 M | 43.5 M | 48.1 M | 50.9 M | 67.3 M | 78.5 M | 86.6 M | 28.6 M | 37 M | 36 M | 39.6 M | 45.9 M | 23.3 M | 28 M | 21.6 M | 25.7 M | 29.5 M | 20.5 M | 24.9 M | 28.7 M | 31.5 M | 13.8 M | 6.28 M | 8.26 M | 9.81 M | -39.6 M | -40.2 M | -40.2 M | -40.2 M | -40.2 M | -54.4 M | - | - | - | -15.5 M | - | - | - |
Quarterly performance
Select metrics to display
All numbers in USD currency
Balance Sheet is a fundamental financial report of Aldeyra Therapeutics, providing a complete picture of the company’s financial position at a specific point in time. Unlike the income statement, which records the results of operations over a certain period, the balance sheet shows what assets the company owns, what liabilities it has to creditors, and what equity is available to the owners.
For an investor, the balance sheet is important because it allows assessing the company’s financial stability, understanding how much debt it carries, and how dependent it is on borrowed financing. It helps calculate key liquidity and leverage ratios. When analyzing, attention should be paid to the debt-to-equity ratio (Debt/Equity), the amount of cash on the balance sheet, and the ratio of current liabilities to liquid assets.
Features of balance sheet analysis- Vertical and horizontal analysis
Vertical analysis shows the structure of the balance sheet as a percentage of total assets or liabilities, while horizontal analysis shows the dynamics of changes over multiple periods. - Asset quality
It is important to evaluate not only the amount of assets but also their liquidity and realizability. - Accounting for off-balance sheet liabilities
Some liabilities may not be directly reflected in the balance sheet, which requires additional attention.
USA
Russia
China
France
Germany
Israel
Britain
Belgium
Canada
Singapore
Bermuda
